Article
Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine.
Cancer discovery - 1 Sept 2018
Aguirre Andrew J, Nowak Jonathan A, Camarda Nicholas D, Moffitt Richard A, Ghazani Arezou A, Hazar-Rethinam Mehlika, Raghavan Srivatsan, Kim Jaegil, Brais Lauren K, Ragon Dorisanne, Welch Marisa W, Reilly Emma, McCabe Devin, Marini Lori, Anderka Kristin, Helvie Karla, Oliver Nelly, Babic Ana, Da Silva Annacarolina, Nadres Brandon, Van Seventer Emily E, Shahzade Heather A, St Pierre Joseph P, Burke Kelly P, Clancy Thomas, Cleary James M, Doyle Leona A, Jajoo Kunal, McCleary Nadine J, Meyerhardt Jeffrey A, Murphy Janet E, Ng Kimmie, Patel Anuj K, Perez Kimberly, Rosenthal Michael H, Rubinson Douglas A, Ryou Marvin, Shapiro Geoffrey I, Sicinska Ewa, Silverman Stuart G, Nagy Rebecca J, Lanman Richard B, Knoerzer Deborah, Welsch Dean J, Yurgelun Matthew B, Fuchs Charles S, Garraway Levi A, Getz Gad, Hornick Jason L, Johnson Bruce E, Kulke Matthew H, Mayer Robert J, Miller Jeffrey W, Shyn Paul B, Tuveson David A, Wagle Nikhil, Yeh Jen Jen, Hahn William C, Corcoran Ryan B, Carter Scott L, Wolpin Brian M
Abstract excerpt
Clinically relevant subtypes exist for pancreatic ductal adenocarcinoma (PDAC), but molecular characterization is not yet standard in clinical care. We implemented a biopsy protocol to perform time-sensitive whole-exome sequencing and RNA sequencing for patients with advanced PDAC. Therapeutically relevant genomic alterations were identified in 48% (34/71) and pathogenic/likely pathogenic germline alterations in...
Read the complete abstract on PubMed